Trial Profile
A Retrospective study to evaluate Mirabegron and BotulinumtoxinA for the management of refractory neurogenic detrusor overactivity in patients with Spinal Cord Injury
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Sep 2018
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary) ; Botulinum-Toxin-A; Cholinergic receptor antagonists
- Indications Overactive bladder
- Focus Therapeutic Use
- 26 Sep 2018 New trial record
- 31 Aug 2018 Results presented at the 48th Annual Meeting of the International Continence Society